Matthias Bodenstedt, Chief Financial Officer, on June 22, 2026, sold 39,120 shares in Moonlake Immunotherapeutics (MLTX) for $862,205. Following the Form 4 filing with the SEC, Bodenstedt has control over a total of 1,115,435 Class A ordinary shares of the company, with 1,115,435 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1821586/000121390026071075/xslF345X05/ownership.xml